All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 66 points (0.4%) at 14,999 as of Wednesday, July 3, 2013, 12:51 PM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,690 declining with 89 unchanged. The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 1.5%, Celgene Corporation ( CELG), up 1.2% and Biogen Idec ( BIIB), up 0.6%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.1%, and Eli Lilly and Company ( LLY), down 0.9%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $0.50 (1.7%) to $29.73 on average volume. Thus far, 266,173 shares of Grifols exchanged hands as compared to its average daily volume of 636,800 shares. The stock has ranged in price between $28.90-$29.74 after having opened the day at $29.04 as compared to the previous trading day's close of $29.23. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $16.5 billion and is part of the health care sector. Shares are up 14.4% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.